Health News
Markets, macro and movers — curated.
Tuesday's Movers: Eli Lilly and Etsy Upgraded, Dave & Buster's Falls on Weak Earnings
Eli Lilly (LLY) and Etsy (ETSY) win analyst upgrades on obesity leadership and AI shopping, while Dave & Buster's (PLAY) drops over 7% on a weak quarter.
Friday's First Moves: RH Beats, Kroger Cuts Outlook, Novo Nordisk Downgraded
RH (RH) beat Q2 estimates on a tariff refund, Kroger (KR) topped earnings but cut its sales outlook, and Novo Nordisk (NVO) was downgraded on patent risk.
Beyond Nvidia: Why Space and Healthcare AI Are the Next Big Investment Waves
Nvidia's boom points investors toward the next transformative trends: space infrastructure, satellites, orbital data centers, and AI in healthcare.
Sticky Inflation, Slowing Growth, and Moonshot AI's US Cloud Deals
July PCE rose to 3.7% as growth slowed to 1.5%, while Meta settled for $17B and Moonshot AI courted MSFT, AMZN, and GOOGL.
Treasury Doubles Bond Buybacks as Yields Drop, UAE Cuts Iran Trade, Moderna Vaccine Data
Treasury doubles debt buybacks to cut yields, UAE ends Iran trade, and Moderna surges on positive melanoma vaccine results with Merck.
Why Pepsi Looks Cheap in a Beverage Sector Squeezed by GLP-1s and MAHA
A read on why Pepsi is the most attractive consumer-staples stock, plus a covered-call trade ahead of its earnings, in a beverage sector pressured by GLP-1s and MAHA.
Reading Pfizer's Chart: A Bearish Options Setup Near 52-Week Lows
A technical breakdown of Pfizer near its 52-week low, with a bearish single-put trade built around a recent analyst downgrade.
Monday's Market Movers: Micron's AI Surge, Credo's Optical Bet, and AbbVie's Apogee Acquisition
An analysis of early trading moves in Micron, Credo, and AbbVie, driven by AI demand, analyst upgrades, and a major pharma acquisition.
How Eli Lilly Pulled Ahead in the GLP-1 Market and an Options Trade to Play It
An analysis of why Eli Lilly now dominates the GLP-1 weight-loss market over Novo Nordisk, plus a defined-risk options trade for playing the stock.
Buying the Dip: Why the AI Expansion Has Room to Run
A bullish case for why current market pullbacks are buying opportunities, anchored in strong earnings, AI-driven demand, and select large-cap stocks.
Three Market Movers: Memory Pricing, Physical AI, and a Pharma Patent Cliff
An analysis of three notable market moves: Micron's memory rebound, Onsemi's physical-AI thesis, and GSK's $10.6 billion acquisition of cancer biotech Nuvalent.
The Memory Boom and the Weight-Loss Race: Reading the Market's Monday Movers
How surging AI-driven demand is reshaping the memory-chip cycle while next-generation obesity drugs redraw the pharmaceutical competitive map.
The Narrowing Bull: AI Concentration, Geopolitical Risk, and the New Frontiers of Tech and Medicine
An analysis of how AI capital spending, geopolitical tension, and breakthrough drug trials are shaping equity markets and the concentrated bull run.
Three Signals Reshaping the AI and Health Markets
How chip partnerships, surging memory demand, and breakthrough weight-loss trial data are converging to reshape technology and healthcare markets.
Federal Backing for Quantum Computing's Dual Path to Medical Breakthroughs
A federal grant supporting superconducting quantum manufacturing endorses both annealing and gate model computing, opening new paths in drug and cancer research.
Future Rich: Rethinking Wealth in a Changed Economy
Why building wealth today demands new rules: adding friction to spending, running the numbers, and reframing financial despair into opportunity.
Two Roads to Quantum: How Annealing and Gate Model Are Bringing Quantum Computing to Market
An examination of how dual-platform quantum computing—annealing and gate model—is moving from research into commercial use, federal backing, and healthcare.
Three Market Movers to Watch: Memory Stocks, Pharma Acquisitions, and Ferrari's Electric Leap
A look at three notable market developments: surging memory stocks, Eli Lilly's vaccine acquisitions, and Ferrari's debut electric supercar.
The Cannabis Rescheduling Inflection Point: What It Means for Investors
An analysis of how moving cannabis from Schedule I to Schedule III could reshape U.S. cannabis investing, and why caution still matters.
The Peptide Promise: Why Hims & Hers Stumbled Despite a Pivotal Pivot
An analysis of the Hims & Hers earnings miss, the strategic pivot away from compounded GLP-1s, and the peptide opportunity that could redefine the company.